# Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-es-23-008-novel-approaches-for-developmental-neurotoxicity-testing/  
Official notice: https://www.grants.gov/search-results-detail/347009

> National Institutes of Health offered grants of up to $295,924 to small businesses. Applications closed on July 7, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-ES-23-008 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | July 7, 2023 |
| Award ceiling | $295,924 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.113 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT.

## Questions people ask

### Is RFA-ES-23-008 still open?

No. It closed on July 7, 2023.

### Who can apply for Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)?

Closed July 7, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $295,924 each.

### Who has been funded under RFA-ES-23-008?

NIH RePORTER lists 4 projects funded under RFA-ES-23-008 in fiscal 2024 to 2025, at 4 institutions. The most were at Vala Sciences, Inc., Nemametrix, Inc., Vivoverse, LLC.

### Who has won Environmental Health grants before?

The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.